['prostate cancer']
['leuprolide acetate fluidcrystal® injection depot', 'leuprolide acetate']

        Inclusion Criteria:

          -  Men ≥40 and ≤85 years of age

          -  Histological or cytological proven adenocarcinoma of the prostate requiring hormone
             therapy

          -  Life expectancy over 12 months

          -  World Health Organisation/ The Eastern Cooperative Oncology Group (WHO/ECOG)
             performance status of 0, 1 or 2

          -  Adequate and stable renal function

          -  Adequate and stable hepatic function

        Exclusion Criteria:

          -  Evidence of brain metastasis, spinal cord compression, or urinary tract obstruction

          -  Serum Testosterone levels below 150 ng/dL at Screening visit

          -  Medical or radiological prostate cancer treatments within 2 months prior to the
             Screening visit

          -  Surgical treatment of prostate cancer within 2 weeks prior to the Screening visit

          -  Prior orchiectomy, hypophysectomy, or adrenalectomy

          -  Prior use of LHRH agonists within 12 months prior to the Screening visit and during
             the study
      